Nanjing Hicin Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

152.89

P/S

12.19

EPS

0.34

Div Yield, %

0.10%

Shrs. gr., 5y

—

Rev. gr., 5y

-11.41%

Revenues

504m

-2.60%

Net income

40m

+10.75%

CFO

60m

+150.54%

Dividend

Jun 18, 20240.05 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Nanjing Hicin Pharmaceutical Co., Ltd. engages in the research, development, manufacture, marketing, and sale of pharmaceutical preparations and synthetic chemicals in China. The company offers antivirals, antibiotics, endocrine drugs, gastrointestinal drugs, orthopedic drugs, drugs for cardio-cerebral system, and immuno-modulate agents. It also provides technical transferring services. The company also exports APIs; omeprazole sodium and cefepime hydrochloride for injections; and lansoprazole tablets to South-Asian countries, South-American countries, and European countries. Nanjing Hicin Pharmaceutical Co., Ltd. was founded in 2003 and is based in Nanjing, China.

URL

https://www.hicin.cn/page1/index1

IPO date

Jan 12, 2017

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT